120 related articles for article (PubMed ID: 16835966)
1. Multiple myeloma: new options, new challenges.
Lacy MQ
Mayo Clin Proc; 2006 Jul; 81(7):877-9. PubMed ID: 16835966
[No Abstract] [Full Text] [Related]
2. New agents and approaches in the treatment of multiple myeloma.
Anderson KC
Clin Adv Hematol Oncol; 2003 Mar; 1(3):151-2. PubMed ID: 16224394
[No Abstract] [Full Text] [Related]
3. Clinical trial designs for multiple myeloma.
Hoering A; Crowley J
Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs in multiple myeloma.
Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in multiple myeloma.
Sirohi B; Powles R
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1559-70. PubMed ID: 19895240
[TBL] [Abstract][Full Text] [Related]
6. New drugs in multiple myeloma.
Berenson JR; Yellin O
Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
[TBL] [Abstract][Full Text] [Related]
7. A strategic framework for novel drug development in multiple myeloma.
Anderson KC; Hannah AL; Pazdur R; Farrell AT
Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
[No Abstract] [Full Text] [Related]
8. The role of thalidomide in multiple myeloma.
Schwab C; Jagannath S
Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
[TBL] [Abstract][Full Text] [Related]
9. Progress in treating multiple myeloma. Thanks to a host of effective new therapies, patients are enjoying years in remission from this malignant blood cancer.
Harv Womens Health Watch; 2010 Jul; 17(11):4-6. PubMed ID: 20684078
[No Abstract] [Full Text] [Related]
10. Development of effective new treatments for multiple myeloma.
Anderson KC; Pazdur R; Farrell AT
J Clin Oncol; 2005 Oct; 23(28):7207-11. PubMed ID: 16145064
[No Abstract] [Full Text] [Related]
11. [Efficacy of novel agents for patients with newly diagnosed symptomatic multiple myeloma].
Sunami K
Rinsho Ketsueki; 2012 Jun; 53(6):580-6. PubMed ID: 22790632
[No Abstract] [Full Text] [Related]
12. Understanding novel therapeutic agents for multiple myeloma.
Tariman JD
Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
[No Abstract] [Full Text] [Related]
14. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Prince HM; Schenkel B; Mileshkin L
Leukemia; 2007 Apr; 21(4):818-20; author reply 821. PubMed ID: 17301817
[No Abstract] [Full Text] [Related]
15. Chemotherapy of multiple myeloma: melphalan--40 years old and still going strong.
Bergsagel PL
Biol Blood Marrow Transplant; 2003 Jan; 9(1):2-3. PubMed ID: 12533738
[No Abstract] [Full Text] [Related]
16. Bortezomib.
Paramore A; Frantz S
Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
[No Abstract] [Full Text] [Related]
17. [Proteasome inhibitors for multiple myeloma].
Yano H; Iida S
Nihon Rinsho; 2007 Jan; 65 Suppl 1():601-4. PubMed ID: 17476759
[No Abstract] [Full Text] [Related]
18. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
19. Novel agents and the paradigm of continuous treatment in multiple myeloma.
Palumbo A
Leuk Res; 2012 Nov; 36 Suppl 1():S1-2. PubMed ID: 23176718
[No Abstract] [Full Text] [Related]
20. Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.
Manasanch EE; Korde N; Mailankody S; Tageja N; Bhutani M; Roschewski M; Landgren O
Haematologica; 2014 Dec; 99(12):1769-71. PubMed ID: 25472951
[No Abstract] [Full Text] [Related]
[Next] [New Search]
